Lymphoma Hub
Avsnitt

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL?

Lymphoma Hub
Dela

The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel (zamto-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)? 


This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. 

Hosted on Acast. See acast.com/privacy for more information.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Scientific Education Support. Innehållet i podden är skapat av Scientific Education Support och inte av, eller tillsammans med, Poddtoppen.